Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics

JS-K, a nitric oxide-releasing diazeniumdiolates, is effective against various tumors. We have discovered that JS-K was effective against Hepatitis B virus (HBV)-positive HepG2.2.15 cells. This study used iTRAQ to identify differentially expressed proteins following JS-K treatment of HepG2.2.15 cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhengyun, Xu, Yan, Zhang, Wanling, Gao, Xinghong, Luo, Guo, Song, Hong, Liu, Jie, Wang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129129/
https://www.ncbi.nlm.nih.gov/pubmed/34001947
http://dx.doi.org/10.1038/s41598-021-90001-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129129/
https://www.ncbi.nlm.nih.gov/pubmed/34001947
http://dx.doi.org/10.1038/s41598-021-90001-3

Ejemplares similares